

Illumina Inc (ILMN) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/ID99C583332CEN.html

Date: March 2021

Pages: 68

Price: US\$ 125.00 (Single User License)

ID: ID99C583332CEN

Abstracts

Illumina Inc (ILMN) - Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.



Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and for cancer. The company's portfolio encompasses sequencing kits and reagents; sequencing tools and systems; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; and instrument services, training and consulting. Illumina serves pharmaceutical companies, academic institutions, genomic research centers, biotechnology companies and clinical research organizations. The company sells its products through direct sales and distributors in the Americas, Asia-Pacific, Europe, the Middle East and Africa. Illumina is headquartered in San Diego, California, the US.

Illumina Inc Key Recent Developments

Feb 23,2021: US Court grants MGI's motion to amend in suit against Illumina

Feb 11,2021: Illumina reports financial results for fourth quarter and fiscal year 2020

Feb 08,2021: Illumina acelerator invests in nine genomics startups for second global

cycle

Jan 31,2021: Illumina and Sequoia Capital China partner to launch genomics incubator in China



Jan 21,2021: MGI concurs with UK court's ruling to invalidate Illumina's patent

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.



Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Illumina Inc - Key Facts

Illumina Inc - Key Employees

Illumina Inc - Key Employee Biographies

Illumina Inc - Major Products and Services

Illumina Inc - History

Illumina Inc - Company Statement

Illumina Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

SECTION 2 - COMPANY ANALYSIS

Company Overview

Illumina Inc - Business Description

Product Category: Consumables

Overview

Performance

Product Category: Instruments

Overview

Performance

Product Category: Service and Other Revenue

Overview

Performance

Product Category: Microarray Products

Performance

Product Category: Sequencing Platforms

Performance

Geographical Segment: Americas

Performance

Geographical Segment: Asia-Pacific (Excluding Greater China)

Performance

Geographical Segment: Europe, Middle East, and Africa

Performance

Geographical Segment: Greater China



Performance

R&D Overview

Illumina Inc - Corporate Strategy

Illumina Inc - SWOT Analysis

SWOT Analysis - Overview

Illumina Inc - Strengths

Illumina Inc - Weaknesses

Illumina Inc - Opportunities

Illumina Inc - Threats

Illumina Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Illumina Inc, Medical Equipment, Deals By Year, 2015 to YTD 2021

Illumina Inc, Medical Equipment, Deals By Type, 2015 to YTD 2021

Illumina Inc, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Feb 23, 2021: US Court grants MGI's motion to amend in suit against Illumina

Feb 11, 2021: Illumina reports financial results for fourth quarter and fiscal year 2020

Feb 08, 2021: Illumina acelerator invests in nine genomics startups for second global

cycle

Jan 31, 2021: Illumina and Sequoia Capital China partner to launch genomics incubator

in China

Jan 21, 2021: MGI concurs with UK court's ruling to invalidate Illumina's patent

Jan 20, 2021: Illumina wins patent infringement suit against BGI in the UK

Jan 11, 2021: New bioinformatics solution powers multi-omics discovery at massive

scale

Dec 08, 2020: Illumina and Harvard Pilgrim Health Care expand access to whole-



genome sequencing for genetic disease testing

Dec 03, 2020: Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina

Collaborate on Scalable Clinical Whole-Genome Sequencing Initiative

Dec 03, 2020: NYGC collaborates on clinical whole-genome sequencing initiative to

expand patient access to advanced genomic technologies

SECTION 6 – APPENDIX

Methodology Ratio Definitions About GlobalData Contact Us Disclaimer



List Of Tables

LIST OF TABLES

Illumina Inc, Key Facts

Illumina Inc, Key Employees

Illumina Inc, Key Employee Biographies

Illumina Inc, Major Products and Services

Illumina Inc, History

Illumina Inc, Other Locations

Illumina Inc, Subsidiaries

Illumina Inc, Joint Venture

Illumina Inc, Key Competitors

Illumina Inc, Ratios based on current share price

Illumina Inc, Annual Ratios

Illumina Inc, Annual Ratios (Cont...1)

Illumina Inc, Annual Ratios (Cont...2)

Illumina Inc, Interim Ratios

Illumina Inc, Medical Equipment, Deals By Year, 2015 to YTD 2021

Illumina Inc, Medical Equipment, Deals By Type, 2015 to YTD 2021

Illumina Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

Illumina Inc, Performance Chart (2016 - 2020)

Illumina Inc, Ratio Charts

Illumina Inc, Medical Equipment, Deals By Year, 2015 to YTD 2021

Illumina Inc, Medical Equipment, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Illumina Inc (ILMN) - Financial and Strategic SWOT Analysis Review

Product link: https://marketpublishers.com/r/ID99C583332CEN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/ID99C583332CEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970